NIPH Clinical Trials Search

JAPANESE
国立保健医療科学院
JRCT ID: jRCT2051190094

Registered date:15/01/2020

A multicenter extension study of empagliflozin in patients with refractory diabetes mellitus with insulin resistance

Basic Information

Recruitment status Complete
Health condition(s) or Problem(s) studiedInsulin resistance syndrome (type A, type B, type non-A non-B), Lipoatrophic diabetes mellitus
Date of first enrollment26/03/2020
Target sample size8
Countries of recruitmentJapan
Study typeInterventional
Intervention(s)The study treatment shall be started from the next day of the Week 24 visit of the EMPIRE-01 study after enrollment. The investigational drug shall be administered at the same dosage as that of the empagliflozin tablet administered from Week 12 to Week 24 of the treatment period in the EMPIRE-01 study. The administration is oral administration with water once daily before or after breakfast.

Outcome(s)

Primary OutcomePresence/absence of adverse events, adverse drug reactions, and use of rescue treatment drugs until Week 28 (Week 52 of the EMPIRE-01 study)
Secondary Outcome(1)HbA1c change rate at Week 28 (52) of the treatment from baseline The HbA1c change rate at Week 28 (52) from baseline is defined as HbA1c change from baseline divided by baseline HbA1c of the EMPIRE-01 study and multiplied by 100. (2)HbA1c change at Week 28 (52) of the treatment from baseline The HbA1c change at Week 28 (52) of the treatment from baseline is defined as the difference in HbA1c levels between Week 28 (52) and baseline of the EMPIRE-01 study. (3)HbA1c at each time point The HbA1c at each time point is defined as the HbA1c levels at baseline of the EMPIRE-01 study, Week 12 (36), Week 28 (52), or at discontinuation. (4)Fasting plasma glucose (FPG) at each time point The FPG at each time point is defined as the FPG levels at baseline of the EMPIRE-01 study, Week 12 (36), Week 28 (52), or at discontinuation. (5)Fasting plasma glucose (FPG) change at Week 28 (52) of the treatment from baseline The FPG change at Week 28 (52) of the treatment from baseline is defined as the difference in the FPG levels between Week 28 (52) and baseline of the EMPIRE-01 study. (6)Insulin dose at each time point (TDD, TBD) The TDD and TBD at each time point are defined as the insulin doses at baseline of the EMPIRE-01 study, Week 12 (36), Week 28 (52), or at discontinuation. (7)Postprandial glucose for 2 hours over time Postprandial glucose for 2 hours shall be measured for 14 days starting from Week 12 (36) by using FreeStyle Libre ProTM.

Key inclusion & exclusion criteria

Age minimum>= 20age old
Age maximumNot applicable
GenderBoth
Include criteria(1)It is an extension study of the EMPIRE-01 study (2)Based on the Article 50 of GCP Ordinance
Exclude criteria(1)A patient with a medical history of acute coronary syndrome (including non-ST-elevation myocardial infarction, ST-elevation myocardial infarction and unstable angina pectoris), stroke or transient ischemic attack (TIA) within 3 months before obtaining consent (2)A patient with suspected hepatic dysfunction that either of serum ALT, AST or alkaline phosphatase is exceeding 3-fold of upper limit of normal range prior to starting extension study treatment (Day 0) (3)A patient who is receiving a systemic steroid at the time of consent (except for type B) (4)A patient whose thyroid hormone product dose has been changed within 6 weeks before obtaining consent (5)A patient with unstable endocrine diseases other than diabetes mellitus (6)A patient with hemolysis or blood diseases that destabilize erythrocytic cells and other various disorders (e.g., malaria, babesiosis, hemolytic anemia) (7)A premenopausal female patient (the latest menstruation was within 1 year before obtaining consent), a lactating or pregnant patient, or a patient who may be pregnant (without hysterectomy or ovariectomy) who has no intention to use efficacious contraception defined in this study during the study period and would not agree to receive regular pregnancy tests during the study period (8)A patient who has experienced alcohol abuse or drug abuse within 3 months before obtaining consent, which may disturb the study participation (9)A patient who is in the condition that makes it difficult to administer the study drug (10)A patient with renal dysfunction of eGFR (MDRD calculating formula) <45 mL/min/1.73 m2 prior to starting extension study treatment (Day 0) (11)A patient who indicates a hypersensitivity response to empagliflozin or its excipients, or a patient with lactose-intolerance (12)A patient with severe ketosis, diabetic coma or precoma, severe infection, perioperative status, or serious trauma (13)A patient that the investigator and/or subinvestigator, etc., has judged to be ineligible to this study for other reasons

Related Information

Contact

Public contact
Name Yushi Hirota
Address 7-5-2 Kusunoki-cho, Chuo-ku, Kobe Hyogo Japan 650-0017
Telephone +81-78-382-5861
E-mail hirota@med.kobe-u.ac.jp
Affiliation Kobe University Hospital
Scientific contact
Name Wataru Ogawa
Address 7-5-2 Kusunoki-cho, Chuo-ku, Kobe Hyogo Japan 650-0017
Telephone +81-78-382-5861
E-mail ogawa@med.kobe-u.ac.jp
Affiliation Kobe University Hospital